NEW YORK, NY--(Marketwire -07\/17\/12)- The Biotechnology Industry has been soaring in 2012 as companies -- both large and small -- have shown impressive growth. The SPDR S&P Biotech ETF (XBI) and the First Trust NYSE Arca Biotech Index ETF (FBT) year-to-date are up 37 percent and 35 percent, respectively, outperforming the broader market by a wide margin. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Cell Therapeutics Inc. (CTIC) and Oncothyreon Inc. (ONTY). <\/p>\n
Access to the full company reports can be found at: <\/p>\n
http:\/\/www.paragonreport.com\/CTIC<\/a> <\/p>\n http:\/\/www.paragonreport.com\/ONTY<\/a> <\/p>\n Despite having to negotiate a more challenging regulation process biotech companies have continued to show investors strong gains in 2012. The FDA Amendments Act of 2007 forced regulators to increase standards for approvals of new drugs, introducing mandatory risk evaluation and mitigation strategies. According to a Pharmaceuticals & Biotechnology report from IMAP, several pharmaceutical firms have altered their drug portfolios from primary care driven blockbusters towards specialties such as oncology, immunology and inflammation, where the medical need is \"so high that prices are more easily accepted by the regulators.\" <\/p>\n Paragon Report releases regular market updates on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http:\/\/www.ParagonReport.com<\/a> and get exclusive access to our numerous stock reports and industry newsletters. <\/p>\n Cell Therapeutics is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. The company last month completed the acquisition of Pacritinib a highly selective JAK2 inhibitor demonstrated encouraging clinical activity in phase 1 and 2 clinical studies of patients with primary myelofibrosis (MF) and MF secondary to other myeloproliferative neoplasms. <\/p>\n Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. <\/p>\n The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http:\/\/www.paragonreport.com\/disclaimer<\/a> <\/p>\n<\/p>\n Go here to read the rest: NEW YORK, NY--(Marketwire -07\/17\/12)- The Biotechnology Industry has been soaring in 2012 as companies -- both large and small -- have shown impressive growth. The SPDR S&P Biotech ETF (XBI) and the First Trust NYSE Arca Biotech Index ETF (FBT) year-to-date are up 37 percent and 35 percent, respectively, outperforming the broader market by a wide margin. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Cell Therapeutics Inc. Continue reading
\nBiotech Companies -- Both Large and Small -- Showing Impressive Growth in 2012<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"